Metis TechBio and Eli Lilly strike drug delivery collaboration worth up to $1.1 billion
Hong Kong-listed Metis TechBio has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies. The deal represents a significant partnership between the biotech firms focused on advancing targeted drug delivery capabilities.
4 sourcesDrug delivery systems
00